Asset
Ristoglogene Autogetemcel
Beam Therapeutics Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05456880 | phase1_2 | active_not_recruiting | 2022-08-30 | 2028-02-01 | Beam Therapeutics Inc. | BEACON: A Study Evaluating the Safety and Efficacy of BEAM-101 in Patients With Severe Sickle Cell Disease |
FDA applications (0)
This company has no applications containing this asset.